6 курс / Кардиология / Джон_Кэмм_Болезни_сердца_и_сосудов_2011
.pdfphenotyping, molecular mechanisms and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function // Circulation. - 2007. - Vol. 116. - P. 2325-2345.
Kuethe F., Sigusch H.H., Hilbig K. et al. Detection of viral genome in the myocardium: lack of prognostic and functional relevance in patients with acute dilated cardiomyopathy // Am. Heart J. - 2007. - Vol. 153. - P. 850-858.
Broder H., Gottlieb R.A., Lepor N.E. Chemotherapy and cardioto-xicity // Rev. Cardiovasc. Med. - 2008. - Vol. 9. - P. 75-83.
MacDonald M.R., Petrie M.C., Hawkins N.M. et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure // Eur. Heart J. - 2008. - Vol. 29. - P. 1224-1240.
Murphy N.F., MacIntyre K., Stewart S. et al. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study) // Eur. Heart J. - 2006. - Vol. 27. - P. 96-106.
Stewart S., Hart C.L., Hole D.J. et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study // Am. J. Med. - 2002. - Vol. 113. - P. 359364.
Jeong Y.H., Choi K.J., Song J.M. et al. Diagnostic approach and treatment strategy in tachycardiainduced cardiomyopathy // Clin. Cardiol. - 2008. - Vol. 31. - P. 172-178.
Shinbane J.S., Wood M.A., Jensen D.N. et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies // J. Am. Coll. Cardiol. - 1997. - Vol. 29. - P. 709-715.
Braunstein J.B., Anderson G.F., Gerstenblith G. et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure // J. Am. Coll. Cardiol. - 2003. - Vol. 42. - P. 1226-1233.
Tang Y.D., Katz S.D. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes // Heart Fail. Rev. - 2008. - Vol. 13. - P. 387-392.
Pocock S.J., McMurray J.J., Dobson J. et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme // Eur. Heart J. - 2008. - Vol. 29. - P. 2641-2650.
Macchia A., Monte S., Pellegrini F. et al. Depression worsens outcomes in elderly patients with heart failure: an analysis of 48,117 patients in a community setting // Eur. J. Heart Fail. - 2008. - Vol. 10. - P. 714-721.
Mookadam F., Calvin A.D., Somers V.K. Prevalence and management of central sleep apnea in heart failure patients // Curr. Heart Fail. Rep. - 2008. - Vol. 5. - P. 233-237.
Petrie C.J., Mark P.B., Weir R.A. Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review // Int. J. Cardiol. - 2008. - Vol. 128. - P. 154-165.
Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials // Lancet. - 2007. - Vol. 370. - P. 1129-1136.
Hudson M., Rahme E., Richard H. et al. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? // Arthritis Rheum. - 2007. - Vol. 57. - P. 516-523.
Shlipak M.G. Pharmacotherapy for heart failure in patients with renal insufficiency // Ann. Intern. Med. - 2003. - Vol. 138. - P. 917-924.
Bongartz L.G., Cramer M.J., Doevendans P.A. et al. The severe cardiorenal syndrome: "Guyton revisited" // Eur. Heart J. - 2005. - Vol. 26. - P. 11-17.
Ronco C., Haapio M., House A.A. et al. Cardiorenal syndrome // J. Am. Coll. Cardiol. - 2008. - Vol. 52. - P. 1527-1539.
Damman K., Navis G., Voors A.A. et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis // J. Card. Fail. - 2007. - Vol. 13. - P. 599-608.
Levy W.C. Anemia in heart failure: marker or mediator of adverse prognosis? // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 577-578.
Murphy N.F., McDonald K. Treatment of anaemia in chronic heart failure - optimal approach still unclear // Eur. Heart J. - 2007. - Vol. 28. - P. 2185-2187.
Groenveld H.F., Januzzi J.L., Damman K. et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis // J. Am. Coll. Cardiol. - 2008. - Vol. 52. - P. 818-827.
Anker S.D., Negassa A., Coats A.J. et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study // Lancet. - 2003. - Vol. 361. - P. 1077-1083.
Von Haehling S., Lainscak M., Springer J. et al. Cardiac cachexia: A systematic overview // Pharmacol. Ther. - 2009. - Vol. 121. - P. 227-252.
Cohn J.N., Ferrari R., Sharpe N. Cardiac remodelling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling // J. Am. Coll. Cardiol. - 2000. - Vol. 35. - P. 569-582.
Mudd J.O., Kass D.A. Tackling heart failure in the twenty first century // Nature. - 2008. - Vol. 451. - P. 919-927.
Divakaran V., Mann D.L. The emerging role of microRNAs in cardiac remodeling and heart failure // Circ. Res. - 2008. - Vol. 103. - P. 1072-1083.
Levick S.P., Brower G.L. Regulation of matrix metalloproteinases is at the heart of myocardial remodeling // Am. J. Physiol. Heart Circ. Physiol. - 2008. - Vol. 295. - P. 1375-1376.
Latini R., Masson S., Staszewsky L. et al. Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling // Curr. Heart Fail. Rep. - 2006. - Vol. 3. - P. 157-163.
Mudd J.O., Kass D.A. Reversing chronic remodeling in heart failure // Expert. Rev. Cardiovasc. Ther. - 2007. - Vol. 5. - P. 585-598.
Abrahamsson P., Dobson J., Granger C.B. et al. for the CHARM Investigators. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure // Heart J. - 2009. - Vol. 30. - P. 338-345.
Neubauer S. The failing heart - an engine out of fuel // N. Engl. J. Med. - 2007. - Vol. 356. - P. 1140-1151.
Bleasdale R.A., Frenneaux M.P. Cardiac resynchronisation therapy: when the drugs don’t work // Heart. - 2004. - Vol. 90. - P. 2-4.
Ashrafian H., Williams L., Frenneaux M.P. The pathophysiology of heart failure: a tale of two old paradigms revisited // Clin. Med. - 2008. - Vol. 8. - P. 192-197.
Elliott P., Andersson B., Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases // Eur. Heart J. - 2008. - Vol. 29. - P. 270-276.
Deo R., MacRae C.A. The genetics of cardiomyopathies: what clinicians should know // Curr. Heart Fail. Rep. - 2007. - Vol. 4. - P. 229-235.
Malcom J., Arnold O., Howlett J.G. et al. Canadian Cardiovascular Society. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure - 2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies // Can. J. Cardiol. - 2008. - Vol. 24. - P. 21-40.
Kitzman D.W. Diastolic dysfunction: one piece of the heart failure with normal ejection fraction puzzle // Circulation. - 2008. - Vol. 117. - P. 2044-2046.
Paulus W.J., Tschöpe C., Sanderson J.E. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology // Eur. Heart J. - 2007. - Vol. 28. - P. 2539-2550.
Martos R., Baugh J., Ledwidge M. et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction // Circulation. - 2007. - Vol. 115. - P. 888-895.
Lam C.S., Roger V.L., Rodeheffer R.J. et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota // Circulation. - 2007. - Vol. 115. - P. 1982-1990.
Cohen-Solal A., Logeart D., Tartiere J.M. "Diastolic" heart failure, overlooked systolic dysfunction, altered ventriculo-arterial coupling or limitation of cardiac reserve? // Int. J. Cardiol. - 2008. - Vol. 128. - P. 299303.
Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle // N. Engl. J. Med. - 2004. - Vol. 350. - P. 1953-1959.
Kushwaha S.S., Fallon J.T., Fuster V. Restrictive cardiomyopathy // N. Engl. J. Med. - 1997. - Vol. 336. - P. 267-276.
Eshaghian S., Kaul S., Shah P.K. Cardiac amyloidosis: new insights into diagnosis and management // Rev. Cardiovasc. Med. - 2007. - Vol. 8. - P. 189-199.
Kim J.S., Kim H.H., Yoon Y. Imaging of pericardial diseases // Clin. Radiol. - 2007. - Vol. 62. - P. 626-631.
Goldstein J.A. Cardiac tamponade, constrictive pericarditis, and restrictive cardiomyopathy // Curr. Probl. Cardiol. - 2004. - Vol. 29. - P. 503-567.
Zile M.R., Gaasch W.H. Heart failure in aortic stenosis - improving diagnosis and treatment // N. Engl. J. Med. - 2003. - Vol. 348. - P. 1735-1736.
Borer J.S., Truter S.L., Gupta A. et al. Heart failure in aortic regurgitation: the role of primary fibrosis and its cellular and molecular pathophysiology // Adv. Cardiol. - 2004. - Vol. 41. - P. 16-24.
Mehra M.R., Gheorghiade M., Bonow R.O. Mitral regurgitation in chronic heart failure: more questions than answers? // Curr. Cardiol. Rep. - 2004. - Vol. 6. - P. 96-99.
Weil J., Eschenhagen T., Hirt S. et al. Preserved Frank-Starling mechanism in human end stage heart failure // Cardiovasc. Res. - 1998. - Vol. 37. - P. 541-548.
Sandler H., Dodge H.T. Left ventricular tension and stress in man // Circ. Res. - 1963. - Vol. 13. - P. 91.
Opie L.H., Commerford P.J., Gersh B.J. et al. Controversies in ventricular remodelling // Lancet. - 2006. - Vol. 367. - P. 356-367.
Spann J.F., Buccino R.A., Sonnenblick E.H. et al. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure // Circ. Res. - 1967. - Vol. 21. - P. 341-354.
Nishida K., Yamaguchi Otsu K. et al. Crosstalk between autophagy and apoptosis in heart disease. Circ Res 2008. - Vol. 103. - P. 343-351.
Francis G.S., Cohn J.N. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention // FASEB J. - 1990. - Vol. 4. - P. 3068-3075.
Harris P. Biology of cardiac failure // Eur. Heart J. - 1982. - Vol. 3. - Suppl. D. - P. 5-10.
De Sa D.D., Chen H.H. The role of natriuretic peptides in heart failure // Curr. Cardiol. Rep. - 2008. - Vol. 10. - P. 182-189.
Bunton D.C., Petrie M.C., Hillier C. et al. The clinical relevance of adrenomedullin: a promising profile? // Pharmacol. Ther. - 2004. - Vol. 103. - P. 179-201.
Hogg K., McMurray J. Neurohumoral pathways in heart failure with preserved systolic function // Prog. Cardiovasc. Dis. - 2005. - Vol. 47. - P. 357-366.
Braunwald E., Harrison D.C., Chidsey C.A. The heart as an endocrine organ // Am. J. Med. - 1964. - Vol. 36. - P. 1-4.
Francis G.S., Cohn J.N. The autonomic nervous system in congestive heart failure // Annu. Rev. Med. - 1986. - Vol. 37. - P. 235-247.
Tsutamoto T., Nishiyama K., Sakai H. et al. Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure // Eur. J. Heart. Fail. - 2008. - Vol. 10. - P. 1208-1214.
Cohn J.N., Levine T.B., Olivari M.T. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure // N. Engl. J. Med. - 1984. - Vol. 311. - P. 819-823.
Unger T., Li J. The role of the renin-angiotensin-aldosterone system in heart failure // J. Renin Angiotensin Aldosterone Syst. - 2004. - Vol. 5. - Suppl. 1. - P. 7-10.
Epelman S., Tang W.H., Chen S.Y. et al. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system // J. Am. Coll. Cardiol. - 2008. - Vol. 52. - P. 750-754.
Levine T.B., Cohn J.N., Vrobel T., Franciosa J.A. High renin in heart failure: a manifestation of hyponatremia // Trans. Assoc. Am. Physicians. - 1979. - Vol. 92. - P. 203-207.
Pitt B. Aldosterone blockade in patients with chronic heart failure // Cardiol. Clin. - 2008. - Vol. 26. - P. 1521.
Batenburg W.W., Jan Danser A.H. The (pro)renin receptor: a new addition to the renin-angiotensin system? // Eur. J. Pharmacol. - 2008. - Vol. 585. - P. 320-324.
Goldsmith S.R., Gheorghiade M. Vasopressin antagonism in heart failure // J. Am. Coll. Cardiol. - 2005. - Vol. 46. - P. 1785-1791.
Finley J.J.4th, Konstam M.A., Udelson J.E. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia // Circulation. - 2008. - Vol. 118. - P. 410-421.
Daniels L.B., Maisel A.S. Natriuretic peptides // J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 2357-2368.
Richards A.M. Natriuretic peptides: update on Peptide release, bioactivity and clinical use // Hypertension. - 2007. - Vol. 50. - P. 25-30.
Lee C.Y., Burnett J.C.Jr. Natriuretic peptides and therapeutic applications // Heart Fail. Rev. - 2007. - Vol. 12. - P. 131-142.
Akashi Y.J., Springer J., Lainscak M. et al. Atrial natriuretic peptide and related peptides // Clin. Chem. Lab. Med. - 2007. - Vol. 45. - P. 1259-1267.
Chandrasekaran B., Dar O., McDonagh T. The role of apelin in cardiovascular function and heart failure // Eur. J. Heart. Fail. - 2008. - Vol. 10. - P. 725-732.
Tang W.H., Francis G.S. Exploring new drugs for heart failure: the case of urocortin // Eur. Heart J. - 2007. - Vol. 28. - P. 2561-2562.
Fisher C., MacLean M., Morecroft I. et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? // Circulation. - 2002. - Vol. 106. - P. 292-295.
Teerlink J.R., Metra M., Felker G.M. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study // Lancet. - 2009. - Vol. 373. - P. 1429-1439.
Drexler H., Hayoz D., Munzel T. et al. Endothelial function in chronic congestive heart failure // Am. J. Cardiol. - 1992. - Vol. 69. - P. 1596-601.
Hambrecht R., Adams V., Gielen S. et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle // J. Am. Coll. Cardiol. - 1999. - Vol. 33. - P. 174-179.
Cowburn P.J., Cleland J.G. Endothelin antagonists for chronic heart failure: do they have a role? // Eur. Heart J. - 2001. - Vol. 22. - P. 1772-1784.
McMurray J., Chopra M., Abdullah I. et al. Evidence of oxidative stress in chronic heart failure in humans // Eur. Heart J. - 1993. - Vol. 14. - P. 1493-1498.
Grieve D.J., Shah A.M. Oxidative stress in heart failure. More than just damage // Eur. Heart J. - 2003. - Vol. 24. - P. 2161-2163.
Landmesser U., Spiekermann S., Dikalov S. et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase // Circulation. - 2002. - Vol. 106. - P. 3073-3078.
Berry C., Hamilton C.A., Brosnan M.J. et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries //
Circulation. - 2000. - Vol. 101. - P. 2206-2212.
Doehner W., Springer J., Landmesser U. et al. Uric acid in chronic heart failure - current pathophysiological concepts // Eur. J. Heart. Fail. - 2008. - Vol. 10. - P. 1269-1270.
Hare J.M., Mangal B., Brown J. et al. OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of theOPT-CHF study // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 2301-2309.
Keith M.E., Jeejeebhoy K.N., Langer A. et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure // Am. J. Clin. Nutr. - 2001. - Vol. 73. - P. 219-224.
Heymans S., Hirsch E., Anker S. et al. Inflammation as a therapeutic target in heart failure? A Scientific Statement From the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology // Eur. J. Heart Failure. - 2009. - Vol. 11. - P. 119-129.
Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis // Lancet. - 2000. - Vol. 356. - P. 930-933.
Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) // Circulation. - 2004. - Vol. 109. - P. 1594-1602.
Chung E.S., Packer M., Lo K.H. et al. Anti-ФНО Therapy Against Congestive Heart Failure Investigators.
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-ФНО Therapy Against Congestive Heart Failure (ATTACH) trial // Circulation. - 2003. - Vol. 107. - P. 31333140.
Mancini D.M. Pulmonary factors limiting exercise capacity in patients with heart failure // Prog. Cardiovasc. Dis. - 1995. - Vol. 37. - P. 347.
Piepoli M., Ponikowski P., Clark A.L. A neural link to explain the ‘muscle hypothesis’ of exercise intolerance in chronic heart failure // Am. Heart J. - 1999. - Vol. 137. - P. 1050-1056.
Geltman E.M. Mild heart failure: diagnosis and treatment // Am. Heart J. - 1989. - Vol. 118. - P. 1277. Clark A.L. Origin of symptoms in chronic heart failure // Heart. - 2006. - Vol. 92. - P. 12-16.
Davie A.P., Francis C.M., Caruana L. et al. Assessing diagnosis in heart failure: which features are any use? // Q. J. Med. - 1997. - Vol. 90. - P. 335-339.
Madhok V., Falk G., Rogers A. et al. The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review // BMC Fam. Pract. - 2008. - Vol. 9. - P. 56.
Anselm A.H., Gauthier N., Beanlands R.S. et al. Sleep apnea in chronic heart failure // Curr. Opin. Cardiol. - 2008. - Vol. 23. - P. 121-126.
Criteria Committee, New-York Association, Inc. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis, 6th edn. - Boston: Little Brown & Co., 1964. - P. 114.
Marantz P.R., Tobin J.N., Wassertheil-Smoller S. et al. The relationship by clinical criteria // Circulation. - 1988. - Vol. 77. - P. 607-612.
Khot U.N., Jia G., Moliterno D.J. et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification // JAMA. - 2003. - Vol. 290. - P. 2174-2181.
Rector T.S., Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomised, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group // Am. Heart J. - 1992. - Vol. 124. - P. 1017-1025.
Spertus J.A., Jones P.G., Kim J. et al. Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients // Qual. Life Res. - 2008. - Vol. 17. - P. 291-298.
Spiteri M.A., Cook D.G., Clarke S.W. Reliability of eliciting physical signs in examination of the chest // Lancet. - 1988. - Vol. 1. - P. 873-875.
Butman S.M., Ewy G.A., Standen J.R. et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension // J. Am. Coll. Cardiol. - 1993. - Vol. 22. - P. 968-974.
Lok C.E., Morgan C.D., Ranganathan N. The accuracy and interobserver agreement in detecting the "gallop sounds" by cardiac auscultation // Chest. - 1998. - Vol. 114. - P. 1283-1288.
Drazner M.H., Rame J.E., Stevenson L.W., Dries D.L. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure // N. Engl. J. Med. - 2001. - Vol. 345. -
P. 574-581.
Rihal C.S., Davis K.B., Kennedy J.W. et al. The utility of clinical, electrocardiographic and roentgenographic variables in the prediction of left ventricular function // Am. J. Cardiol. - 1995. - Vol. 75. - P. 220-223.
Clark A.L., Goode K., Cleland J.G. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure // Eur. J. Heart Fail. - 2008. - Vol. 10. - P. 696-702.
Hawkins N.M., Wang D., McMurray J.J. et al. CHARM Investigators and Committees. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme // Eur. J. Heart Fail. - 2007. - Vol. 9. - P. 510-517.
Gillespie N.D., McNeill G., Pringle T. et al. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea // BMJ. - 1997. - Vol. 314. - P. 936-940.
Petrie M.C., McMurray J.J.V. It cannot be cardiac failure because the heart is not enlarged on the chest X-ray // Eur. J. Heart Fail. - 2003. - Vol. 5. - P. 117-119.
Chakko S., Woska D., Martinez H. et al. Clinical, radiographic and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care // Am. J. Med. - 1991. -
Vol. 90. - P. 353-359.
Peacock W.F.4th, De Marco T., Fonarow G.C. et al. ADHERE Investigators. Cardiac troponin and outcome in acute heart failure // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2117-2126.
Tang W.H., Francis G.S., Morrow D.A. et al. National Academy of Clinical Biochemistry Laboratory Medicine. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure // Circulation. - 2007. - Vol. 116. - P. 99-109.
Gheorghiade M., Konstam M.A., Burnett J.C.Jr. et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan(EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials // JAMA. - 2007. - Vol. 297. - P. 1332-1343.
Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalaemia after publication of the Randomized Aldactone Evaluation Study // N. Engl. J. Med. - 2004. - Vol. 351. - P. 543-551.
Allen L.A., Felker G.M., Pocock S. et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program // Eur. J. Heart Fail. - 2009. - Vol. 11. - P. 170-177.
Felker G.M., Allen L.A., Pocock S.J. et al. CHARM Investigators.Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank // J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 40-47.
Maisel A., Mueller C., Adams K.Jr. et al. State of the art: using natriuretic peptide levels in clinical practice // Eur. J. Heart Fail. - 2008. - Vol. 10. - P. 824-839.
Vajan R.S., Benjamin E.J., Larson M.G. et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. The Framingham Heart Study // JAMA. - 2002. -
Vol. 288. - P. 1252-1259.
Cleland J.G., Swedberg K., Follath F. et al. The Euro Heart Failure Survey Progamme: a survey on the quality of care among patients with heart failure in Europe. Part I: patient characteristics and diagnosis // Eur. Heart J. - 2003. - Vol. 24. - P. 442-463.
Remme W.J., McMurray J.J., Hobbs F.D. et al. SHAPE Study Group. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians // Eur. Heart J. - 2008. - Vol. 29. - P. 1739-1752.
Otterstad J.E., Froeland G., Sutton S.T.M. et al. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function // Eur. Heart J. - 1997. - Vol. 18. - P. 507-513.
Nagueh S.F., Appleton C.P., Gillebert T.C. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography // J. Am. Soc. Echocardiogr. - 2009. - Vol. 22. - P. 107-133.
Whalley G.A., Gamble G.D., Dini F.L. et al. Meta-Analysis Research Group in Echocardiography (MeRGE) Collaborators. Individual patient meta-analyses of restrictive diastolic filling pattern and mortality in patients post acute myocardial infarction and in patients with chronic heart failure // Int. J. Cardiol. - 2007. - Vol. 122. - P. 207-215.
Sicari R., Nihoyannopoulos P., Evangelista A. et al. Stress Echocardiography Expert Consensus Statement - Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC) // Eur. Heart J. - 2009. - Vol. 30. - P. 278-289.
Assomull R.G., Pennell D.J., Prasad S.K. Cardiovascular magnetic resonance in the evaluation of heart failure // Heart. - 2007. - Vol. 93. - P. 985-992.
Task Force of the Italian Working Group on Cardiac Rehabilitation and Prevention (Gruppo Italiano di Cardiologia Riabilitativa e Prevenzione,GICR); Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology, Piepoli M.F., Corrà U. et al. Statement on cardiopulmonary exercise testing in chronic heart failure due toleft ventricular dysfunction: recommendations for performance andinterpretation Part II: How to perform cardiopulmonary exercise testing in chronic heart failure // Eur. J. Cardiovasc. Prev. Rehabil. - 2006. - Vol. 13. - P. 300-311.
Gardner R.S., McDonagh T.A., MacDonald M. et al. Who needs a heart transplant? // Eur. Heart J. - 2006. - Vol. 27. - P. 770-772.
Hawkins N.M., Petrie M.C., Jhund P.S. et al. Heart failure and chronic obstructive pumonary disease: diagnostic pitfalls and epidemiology // Eur. J. Heart Fail. - 2009. - Vol. 11. - P. 130-139.
Binanay C., Califf R.M., Hasselblad V. et al. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial // JAMA. - 2005. - Vol. 294. - P. 1625-1633.
Cleland J.C., Pennell D.J., Ray S.G. et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial //
Lancet. - 2003. - Vol. 362. - P. 14-21.
Cooper L.T., Baughman K.L., Feldman A.M. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology //
Eur. Heart J. - 2007. - Vol. 28. - P. 3076-3093.
Nohria A., Tsang S.W., Fang J.C. et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1797-1804.
Pope C.A.3rd, Renlund D.G., Kfoury A.G. et al. Relation of heart failure hospitalization to exposure to fine particulate air pollution // Am. J. Cardiol. - 2008. - Vol. 102. - P. 1230-1234.
Stewart S., McMurray J.J. Chilling findings: the need for winter vigilance in heart failure // J. Card. Fail. - 2006. - Vol. 12. - P. 120-121.
Olsson L.G., Swedberg K., Ducharme A. et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) program // J. Am. Coll. Cardiol. - 2006. - Vol. 47. - P. 1997-2004.
Rivero-Ayerza M., Scholte Op Reimer W., Lenzen M. et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey // Eur. Heart J. - 2008. - Vol. 29. - P. 1618-1624.
Levy W.C., Mozaffarian D., Linker D.T. et al. The Seattle Heart Failure Model: prediction of survival in heart failure // Circulation. - 2006. - Vol. 113. - P. 1424-1433.
Pocock S.J., Wang D., Pfeffer M.A. et al. Predictors of mortality and morbidity in patients with chronic heart failure // Eur. Heart J. - 2006. - Vol. 27. - P. 65-75.
Latini R., Masson S., Anand I. et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT // Eur. Heart J. - 2004. - Vol. 25. - P. 292-299.
Masson S., Latini R., Anand I.S.; on behalf of the Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) // J. Am. Coll. Cardiol. - 2008. - Vol. 52. - P. 997-1003.
Goebel J.A., Van Bakel A.B. Rational use of diuretics in acute decompensated heart failure // Curr. Heart Fail. Rep. - 2008. - Vol. 5. - P. 153-162.
Faris R., Flather M., Purcell H. et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials // Int. J. Cardiol. - 2002. - Vol. 82. - P. 149-158.
Rosenberg J., Gustafsson F., Galatius S. et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature // Cardiovasc. Drugs Ther. - 2005. - Vol. 19. - P. 301-306.
Iyengar S., Abraham W.T. Diuretic resistance in heart failure // Curr. Heart Fail. Rep. - 2006. - Vol. 3. - P. 41-45.
Costanzo M.R. Ultrafiltration in the management of heart failure // Curr. Opin. Crit. Care. - 2008. - Vol. 14. - P. 524-530.
Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators // N. Engl. J. Med. - 1999. - Vol. 341. - P. 709-717.
McMurray J., Cohen-Solal A., Dietz R. et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice // Eur. J. Heart Fail. - 2005. - Vol. 7. - P. 710-721.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group // N. Engl. J. Med. - 1987. - Vol. 316. - P. 1429-1435.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators // N. Engl. J. Med. - 1991. - Vol. 325. - P. 293-302.
Flather M.D., Yusuf S., Køber L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group // Lancet. - 2000. - Vol. 355. - P. 1575-1581.
Granger C.B., McMurray J.J., Yusuf S. et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial // Lancet. - 2003. - Vol. 362. -
P. 772-776.
Maggioni A.P., Anand I., Gottlieb S.O. et al. Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensinconverting enzyme inhibitors // J. Am. Coll. Cardiol. - 2002. - Vol. 40. - P. 1414-1421.
Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure // N. Engl. J. Med. - 2001. - Vol. 345. - P. 1667-1675.
McMurray J.J., Ostergren J., Swedberg K. et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial // Lancet. - 2003. - Vol. 362. - P. 767771.
McKelvie R.S., Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators // Circulation. - 1999. - Vol. 100. - P. 1056-1064.
McKelvie R.S., Rouleau J.L., White M. et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure // Eur. Heart J. - 2003. - Vol. 24. - P. 1727-1734.
Weir R.A., McMurray J.J., Puu M. et al. CHARM Investigators. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial // Eur. J. Heart Fail. - 2008. - Vol. 10. - P. 157-163.
Desai A.S., Swedberg K., McMurray J.J. et al. CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program // J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 1959-1966.
Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study // N. Engl. J. Med. - 2004. - Vol. 351. - P. 543-551.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial // Lancet. - 1999. - Vol. 353. - P. 9-13.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) // Lancet. - 1999. - Vol. 353. - P. 2001-2007.
Hjalmarson A., Goldstein S., Fagerberg B. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group // JAMA. - 2000. -
Vol. 283. - P. 1295-1302.
Packer M., Bristow M.R., Cohn J.N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group // N. Engl. J. Med. - 1996. -
Vol. 334. - P. 1349-1355.
Packer M., Coats A.J., Fowler M.B. et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure // N. Engl. J. Med. - 2001. -
Vol. 344. - P. 1651-1658.
Packer M., Fowler M.B., Roecker E.B. et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study // Circulation. - 2002. - Vol. 106. - P. 2194-2199.
Flather M.D., Shibata M.C., Coats A.J. et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) // Eur. Heart J. - 2005. - Vol. 26. - P. 215-225.
Poole-Wilson P.A., Swedberg K., Cleland J.G. et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial // Lancet. - 2003. - Vol. 362. - P. 7-13.
Pitt B., Remme W., Zannad F. et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction // N. Engl. J. Med. - 2003. - Vol. 348. - P. 1309-1321.
Hood W.B.Jr., Dans A.L., Guyatt G.H. et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis // J. Card. Fail. - 2004. - Vol. 10. - P. 155-164.
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group // N. Engl. J. Med. - 1997. - Vol. 336. - P. 525-533.
Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure // JAMA. - 2003. - Vol. 289. - P. 871-878.
Cohn J.N., Archibald D.G., Ziesche S. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study // N. Engl. J. Med. - 1986. - Vol. 314. - P. 1547-1552.
Cohn J.N., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure // N. Engl. J. Med. - 1991. - Vol. 325. - P. 303-310.
Taylor A.L., Ziesche S., Yancy C. et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure // N. Engl. J. Med. - 2004. - Vol. 351. -
P. 2049-2057.
Gissi-Hf Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial // Lancet. - 2008. - Vol. 372. -
P. 1223-1230.
Packer M., O’Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group // N. Engl. J. Med. - 1996. - Vol. 335. - P. 1107-1114.
Dorszewski A., Göhmann E., Dorszewski B. et al. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study // J. Card. Fail. - 1997. - Vol. 3. - P. 91-96.
Einhorn P.T., Davis B.R., Massie B.M. et al. ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis // Am. Heart J. - 2007. - Vol. 153. - P. 42-53.
Packer M., McMurray J., Massie B.M. et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study // J. Card. Fail. - 2005. - Vol. 11. - P. 12-20.
Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) // Circulation. - 2004. - Vol. 109. - P. 1594-1602.
Cohn J.N., Goldstein S.O., Greenberg B.H. et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1810-1816.
Cohn J.N., Pfeffer M.A., Rouleau J. et al. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) // Eur. J. Heart. Fail. - 2003. - Vol. 5. - P. 659-667.
Van Veldhuisen D.J., Poole-Wilson P.A. The underreporting of results and possible mechanisms of "negative" drug trials in patients with chronic heart failure // Int. J. Cardiol. - 2001. - Vol. 80. - P. 19-27.
Packer M., Carver J.R., Rodeheffe R.J. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group // N. Engl. J. Med. - 1991. - Vol. 325. - P. 1468-1475.
Køber L., Torp-Pedersen C., McMurray J.J. et al. Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2678-2687.
Kjekshus J., Apetrei E., Barrios V. et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure // N. Engl. J. Med. - 2007. - Vol. 357. - P. 2248-2261.
Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial // Lancet. - 2008. - Vol. 372. - P. 1231-1239.
Home P.D., Pocock S.J., Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial // Lancet. - 2009; Jun. 5. [Epub ahead of print.].
Sochalski J., Jaarsma T., Krumholz H.M. et al. What works in chronic care management: the case of heart failure // Health Aff. (Millwood). - 2009. - Vol. 28. - P. 179-189.
Jaarsma T., van der Wal M.H., Lesman-Leegte I. et al. Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) // Arch. Intern. Med. - 2008. - Vol. 168. - P. 316324.
Hauptman P.J., Rich M.W., Heidenreich P.A. et al. Heart Failure Society of America. The heart failure clinic: a consensus statement of the Heart Failure Society of America // J. Card. Fail. - 2008. - Vol. 14. - P. 801-815.
Clark R.A., Inglis S.C., McAlister F.A. et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis // BMJ. - 2007. - Vol. 334. - P. 942.
Bourge R.C., Abraham W.T., Adamson P.B. et al. COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 1073-1079.
Edwardson S.R. Patient education in heart failure // Heart Lung. - 2007. - Vol. 36. - P. 244-252.
Granger B.B., Swedberg K., Ekman I. et al. CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial // Lancet. - 2005. - Vol. 366. - P. 2005-2011.
O’Connor C.M., Whellan D.J., Lee K.L. et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trail // JAMA. - 2009. - Vol. 301. - P. 1439-1450.
Flynn K.E., Piña I.L., Whellan D.J. et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trail // JAMA. - 2009. - Vol. 301. - P. 1451-1459.
Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure // Curr. Heart Fail. Rep. - 2008. - Vol. 5. - P. 110-114.
Fox K., Ford I., Steg P.G. et al. on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial // Lancet. - 2008. - Vol. 372. - P. 807-816.
Roy D., Talajic M., Nattel S. et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure // N. Engl. J. Med. - 2008. - Vol. 358. - P. 2667-2677.
Khan M.N., Jaïs P., Cummings J. et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure // N. Engl. J. Med. - 2008. - Vol. 359. - P. 1778-1785.
Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006. - Vol. 8. - P. 746-837.
Newman C.M., Price A., Davies D.W. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy // Heart. - 1998. - Vol. 79. - P. 121-127.
Riegger G.A., Haeske W., Kraus C. et al. Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment
//
Am. J. Cardiol. - 1987. - Vol. 59. - P. 906-910.